Pathological validation of ¹⁸F-AlF-NOTA-octreotide PET/CT for neuroblastoma.

ABSTRACT: Somatostatin receptor 2 (SSTR2) positron emission tomography/computed tomography (PET/CT) plays an important role in the diagnosis and treatment of neuroblastoma (NB), but it faces the issue of nonspecific uptake. Although the relationship between SSTR PET/CT and SSTR2 expression has been studied in neuroendocrine tumours (NETs), significant differences exist between NB and NETs, and the application of ¹⁸F-AlF-NOTA-octreotide (¹⁸F-OC) PET/CT in NB requires further investigation. This retrospective study assessed the relationship between ¹⁸F-OC PET/CT imaging parameters and immunohistochemical (IHC) scores for the quantification of SSTR2 expression in NB. We obtained imaging and clinical data from patients with initial or treated NB who underwent ¹⁸

SUBMITTER: Liu Y 

PROVIDER: S-EPMC12501237 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature